Brief: Cytocom Inc Provides Updates On Key Clinical Programs For Crohn's Disease, Hematology, Pancreatic Cancer And Covid-19

Statera Biopharma

09/08/2021 13:27

Aug 9 (Reuters) - Cytocom Inc  CBLI.O :
    * CYTOCOM INC. PROVIDES UPDATES ON KEY CLINICAL PROGRAMS FOR
CROHN'S DISEASE, HEMATOLOGY, PANCREATIC CANCER AND COVID-19
    * CYTOCOM INC. - PATIENT ENROLLMENT IN PHASE 3 PEDIATRIC
CROHN'S
DISEASE TRIAL EXPECTED TO INITIATE BY YEAR-END 2021
    * CYTOCOM INC. - EXPLORING DEVELOPMENT OF ENTOLIMOD IN
HEMATOLOGY
INDICATIONS
    * CYTOCOM INC. - PLAN TO INITIATE A CLINICAL TRIAL EXPLORING
CYTO-401 IN PANCREATIC CANCER IN 1H22
    * CYTOCOM INC. - PLAN TO STUDY CYTO-205 IN PATIENTS WITH
ACUTE AND
POST-ACUTE COVID-19
    * CYTOCOM INC. - EXPECTS TO BEGIN A PHASE 2 CLINICAL TRIAL
IN Q3
OF 2021 TO EVALUATE SAFETY AND EFFICACY OF CYTO-205

Source text for Eikon:  ID:nPn73pJ6La 
Further company coverage:  CBLI.O 

 ((Reuters.Briefs@thomsonreuters.com;))